Use of interleukin-2 and macrophages to treat herpes simplex virus infection in neonatal mice.
We have developed a model of therapy for herpes simplex virus (HSV) infection in neonatal mice. Using a lower dose of virus (10(2) plaque-forming units administered intraperitoneally), we have been able to treat infected mice with syngeneic or allogeneic adult mouse macrophages in combination with three doses of human recombinant interleukin-2. Therapy resulted in a 42%-85% survival rate. Although production of antibody to HSV was associated with successful treatment, early administration of antibody did not improve survival.
Kohl
S
S
Program in Infectious Diseases, University of Texas Medical School, Houston 77025.
Loo
L S
LS
D000818:Animals; D000831:Animals, Newborn; D000914:Antibodies, Viral / Q000096:biosynthesis; D000920:Antibody-Dependent Cell Cytotoxicity; D004195:Disease Models, Animal; D006561:Herpes Simplex / Q000628:therapy*; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use*; D008264:Macrophages / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008813:Mice, Inbred ICR; D010529:Peritoneal Cavity / Q000166:cytology; D011994:Recombinant Proteins / Q000627:therapeutic use; D018139:Simplexvirus / Q000276:immunology
D000914:Antibodies, Viral; D007376:Interleukin-2; D011994:Recombinant Proteins